This study focuses on individuals who have obstructive hypertrophic cardiomyopathy (oHCM, a condition in which the heart muscle is abnormally thick) and who also have left ventricular outflow tract (LVOT) obstruction, a condition that interferes with the flow of blood from the heart to the body. The purpose of the study is to compare the effects of an experimental drug called CK-3773274 and placebo (inactive substance) on the exercise abilities and health status of patients with oHCM. The safety and tolerability of CK-3773274 will also be studied. CK-3773274 may reduce symptoms of oHCM by reducing LVOT obstruction. Researchers will measure the amount of CK-3773274 in the blood at various times, as well the effect of the drug on the patient’s oHCM. Throughout the study, participants will continue with their regular (standard-of-care) medications for oHCM. They will be randomly assigned to receive either CK-3773274 or placebo.
What is the full name of this clinical trial?
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION